BioSig Technologies, Inc. entered into a security purchase agreement for the issuance of 196,872 common shares at a price of $0.8127 per share for gross proceeds of $159,997.8744 on January 25, 2023. The transaction included participation from certain institutional and accredited investors. The company has also issued warrants to purchase up to 98,436 shares, at an exercise price of $0.7502 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance for aggregate consideration of $159,997.87.

The securities were offered and sold in reliance on the exemption from registration under the Securities Act of 1933, as amended provided by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act.